These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 30411339)

  • 1. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
    Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
    Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KEAP1/NRF2 signaling pathway mutations in cervical cancer.
    Chu XY; Li ZJ; Zheng ZW; Tao YL; Zou FX; Yang XF
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4458-4466. PubMed ID: 30058679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
    Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
    Liu Z; Deng M; Wu L; Zhang S
    Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
    Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
    Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.
    Sánchez-Ortega M; Garrido A; Cirauqui C; Sanz-Gonzalez L; Hernández MC; González-García A; Obregon K; Ferrer I; Paz-Ares L; Carrera AC
    Redox Biol; 2024 Sep; 75():103305. PubMed ID: 39137583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
    Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
    Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
    Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
    Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 15. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
    Best SA; De Souza DP; Kersbergen A; Policheni AN; Dayalan S; Tull D; Rathi V; Gray DH; Ritchie ME; McConville MJ; Sutherland KD
    Cell Metab; 2018 Apr; 27(4):935-943.e4. PubMed ID: 29526543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
    Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
    Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.
    Hast BE; Goldfarb D; Mulvaney KM; Hast MA; Siesser PF; Yan F; Hayes DN; Major MB
    Cancer Res; 2013 Apr; 73(7):2199-210. PubMed ID: 23382044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
    Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
    Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.